Cover Image

Brentuximab vedotin and radiotherapy for CD30-positive cutaneous T-cell lymphoma: a retrospective multicenter analysis

Background and Objectives While brentuximab vedotin (BV) and radiotherapy (RTx) are established treatment options for CD30-positive cutaneous T-cell lymphoma (CTCL), data on their simultaneous or sequential use regarding efficacy and tolerability remain scarce. In this retrospective analysis, we eva...

Full description

Saved in:
Bibliographic Details
Main Authors: Schummer, Patrick (Author) , Glatzel, Caroline (Author) , Schrüfer, Philipp (Author) , Lawrenz, Ingulf (Author) , Dobos, Gabor (Author) , Wehkamp, Ulrike (Author) , Hüning, Svea (Author) , Stranzenbach, René (Author) , Nicolay, Jan Peter (Author) , Goebeler, Matthias (Author) , Wobser, Marion (Author)
Format: Article (Journal)
Language:English
Published: 2025
In: Journal der Deutschen Dermatologischen Gesellschaft
Year: 2025, Pages: 1-8
ISSN:1610-0387
DOI:10.1111/ddg.15897
Online Access:Verlag, kostenfrei, Volltext: https://doi.org/10.1111/ddg.15897
Verlag, kostenfrei, Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1111/ddg.15897
Get full text
Author Notes:Patrick Schummer, Caroline Glatzel, Philipp Schrüfer, Ingulf Lawrenz, Gabor Dobos, Ulrike Wehkamp, Svea Hüning, René Stranzenbach, Jan P. Nicolay, Matthias Goebeler, Marion Wobser
Description
Summary:Background and Objectives While brentuximab vedotin (BV) and radiotherapy (RTx) are established treatment options for CD30-positive cutaneous T-cell lymphoma (CTCL), data on their simultaneous or sequential use regarding efficacy and tolerability remain scarce. In this retrospective analysis, we evaluated the combination of BV and RTx in patients with CD30-positive CTCL. Patients and Methods We included 14 CD30-positive CTCL patients from six German cancer centers receiving BV; RTx was initiated within a timeframe of 3 months prior/after BV treatment. RTx was mainly applied as a low-dose scheme. Results Adverse events of any grade occurred in 71% of patients, most commonly peripheral neuropathy, neutropenia, and radiodermatitis. Thirteen patients achieved a complete or partial remission as best overall response, however, 50% of all patients showed disease progression. At a median follow-up of 14.4 months, median progression-free survival was 12.0 months, with a 1-year rate of 34.0%. Conclusions The simultaneous or sequential use of RTx during BV treatment was feasible and well tolerated. Future randomized investigations are needed to identify the benefits of this combination treatment regimen as well as adequate dosing of BV and RTx in a prospective manner.
Item Description:Erstmals veröffentlicht: 30. September 2025
Gesehen am 27.11.2025
Physical Description:Online Resource
ISSN:1610-0387
DOI:10.1111/ddg.15897

Similar Items